USAQ QHSLab, Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 856984 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.1%
TTM net income YoY213.1%
TTM EPS YoY150.0%
Revenue 3-yr CAGR29.5%
Net income 3-yr CAGR—
Margins
Gross margin68.2%
Operating margin-2.2%
Net margin14.8%
FCF margin—
EBITDA margin0.3%
Returns
ROE97.8%
ROA25.1%
ROIC (approx.)-23.4%
Asset turnover1.70x
Leverage & solvency
Liabilities / assets14.1%
Debt / equity0.00x
Current ratio2.10x
Interest coverage-1.03x
Cash quality & payout
Operating cash flow / net income-0.54x
Accruals ratio38.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $677,172 | $847,490 | $728,685 | $703,810 | $737,066 | $605,446 | $645,419 | $625,981 |
| Cost of revenue | $208,709 | $257,706 | $257,882 | $215,551 | $243,435 | $206,431 | $215,475 | $213,827 |
| Gross profit | $468,463 | $589,784 | $470,803 | $488,259 | $493,631 | $399,015 | $429,944 | $412,154 |
| R&D expense | $115,074 | $114,621 | $120,909 | $115,707 | $132,769 | $112,364 | $124,033 | $107,530 |
| SG&A expense | $244,705 | $255,416 | $207,822 | $120,952 | $131,415 | $149,818 | $155,523 | $83,400 |
| Operating income | -$50,404 | $45,245 | -$94,380 | $35,506 | $96,251 | $11,526 | -$12,039 | $73,077 |
| Interest expense | $2,741 | $7,215 | $9,526 | $42,519 | $62,840 | $64,484 | $67,570 | $360,744 |
| Pretax income | -$53,145 | $38,030 | -$103,906 | $556,573 | $33,411 | -$52,958 | -$79,609 | — |
| Net income | -$53,145 | $38,030 | -$103,906 | $556,573 | $33,411 | -$52,958 | -$79,609 | -$287,589 |
| EBITDA | -$32,376 | $63,273 | -$76,352 | $53,534 | $114,279 | $29,554 | $24,605 | $109,721 |
| EPS (basic) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | -0.01 | — |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | -0.01 | — |
| Weighted avg. shares (diluted) | 15.03M | 23.08M | 15.03M | — | 19.33M | 11.28M | 11.19M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $190,464 | $317,392 | $362,088 | $636,157 | $158,391 | $168,358 | $61,065 | $157,168 |
| Receivables | $308,923 | $342,886 | $201,202 | $190,610 | $210,131 | $148,191 | $194,978 | $196,089 |
| Inventory | — | $8,814 | $27,517 | $35,790 | $26,619 | $42,264 | $29,192 | $41,779 |
| Current assets | $519,108 | $682,933 | $619,058 | $883,009 | $428,599 | $385,980 | $325,814 | $420,827 |
| Intangibles | $1.23M | $1.25M | $1.27M | $1.29M | $1.31M | $1.32M | $1.34M | $1.36M |
| Total assets | $1.75M | $1.93M | $1.89M | $2.17M | $1.73M | $1.71M | $1.67M | $1.80M |
| Current liabilities | $247,114 | $375,822 | $368,005 | $449,860 | $2.35M | $2.35M | $2.26M | $2.41M |
| Long-term debt | — | — | $36,877 | $90,704 | — | — | — | — |
| Total debt | — | — | $36,877 | $90,704 | — | — | — | — |
| Total liabilities | $247,114 | $375,822 | $368,005 | $546,078 | $2.35M | $2.35M | $2.26M | $2.41M |
| Shareholders' equity | $1.51M | $1.56M | $1.52M | $1.62M | -$610,912 | -$644,323 | -$591,365 | -$607,756 |
| Net debt | — | — | -$325,211 | -$545,453 | — | — | — | — |
| Shares outstanding | 15.03M | 15.03M | 15.03M | 15.03M | 11.28M | 11.28M | 11.28M | 10.81M |
| Cash flow statement | ||||||||
| Operating cash flow | -$126,928 | -$7,819 | -$200,242 | $98,033 | $2,601 | $127,033 | -$49,549 | $55,050 |
| Financing cash flow | $0 | -$36,877 | -$73,827 | $379,733 | -$12,568 | -$19,740 | -$46,554 | $6,173 |
| Depreciation & amortization | $18,028 | $18,028 | $18,028 | $18,028 | $18,028 | $18,028 | $36,644 | $36,644 |
| Stock-based compensation | $5,664 | $0 | $0 | $0 | $0 | $0 | $0 | $1,258 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.